This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-4780v1 69/10/4476    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Roy, H. K. Articles by Backman, V. PubMed PubMed Citation Articles by Roy, H. K. Articles by Backman, V. Related Collections Early Detection Early Detection: Biomarkers: Discovery, Methodology, Validation Early Detection: Imaging

Association between Rectal Optical Signatures and Colonic Neoplasia: Potential Applications for Screening

¹ Department of Medicine, Evanston-Northwestern Healthcare and ² Biomedical Engineering Department, Northwestern University, Evanston, Illinois; ³ Department of Preventive Medicine, Creighton University, Omaha, Nebraska; and ⁴ Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Requests for reprints: Hemant K. Roy, Evanston-Northwestern Healthcare, 2650 Ridge Avenue, Evanston, IL 60201. Phone: 847-570-3115; Fax: 847-733-5041; E-mail: h-roy{at}northwestern.edu.

Key Words: biomedical optics • colorectal cancer • screening

Field carcinogenesis detection represents a promising means for colorectal cancer (CRC) screening, although current techniques (e.g., flexible sigmoidoscopy) lack the requisite sensitivity. The novel optical technology low-coherence enhanced backscattering (LEBS) spectroscopy, allows identification of microscale architectural consequences of the field carcinogenesis in preclinical CRC models with unprecedented accuracy. To investigate the potential clinical translatability of this approach, we obtained biopsies from the normal-appearing rectal mucosa from patients undergoing colonoscopy (n = 219). LEBS signals were recorded through a bench-top instrument. Four parameters characterizing LEBS signal were linearly combined into a single marker. We found that LEBS signal parameters generally mirrored neoplasia progression from patients with no neoplasia, to 5 to 9 mm adenoma and to advanced adenomas. The composite LEBS marker calculated from the LEBS signal paralleled this risk status (ANOVA P < 0.001). Moreover, this was independent of CRC risk factors, benign colonic findings, or clinically unimportant lesions (diminutive adenomas, hyperplastic polyps). For advanced adenomas, the LEBS marker had a sensitivity of 100%, specificity of 80%, and area under the receiver operator characteristic curve of 0.895. Leave-one-out cross-validation and an independent data set (n = 51) supported the robustness of these findings. In conclusion, we provide the first demonstration that LEBS-detectable alterations in the endoscopically normal rectum were associated with the presence of neoplasia located elsewhere in the colon. This study provides the proof of concept that rectal LEBS analysis may potentially provide a minimally intrusive CRC screening technique. Further studies with an endoscopically compatible fiber optic probe are under way for multicenter clinical validation. [Cancer Res 2009;69(10):4476–83]